Trusted Supply of Critical & Orphan Medicines, Worldwide!

Drug: Lorlatinib
Brand: Lorbrena 100mg
Manufacturer /
TM Owner
Pfizer
Origin: USA

Lorbrena 100mg FC Tablet

Lorbrena contains Lorlatinib, a targeted kinase inhibitor. It blocks specific enzymes that drive cancer cell growth and survival, offering a precision alternative to conventional chemotherapy. It is used in the treatment of lung cancer. It is supplied as a fc tablet (100mg). Available on prescription, it forms part of modern, guideline-driven care.
Strength: 100mg
Pack Size: 30s
Storage: 20°C to 25°C
Form: FC Tablet

+91 900 500 9556

Global Shipping : Reliable Global Distribution Network

Express Delivery : Priority Shipping for Every Order

Secure Payments : Trusted Payment Protection System

Disclaimer
All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the 'Manufacturer/ TM Owner' section in compliance with statutory requirements. Read More

Secure Handling

24/7 Worldwide Support

Global Access

Worldwide Access to Health

Cold-Chain Expert

Excellence in Cold-Chain

Trusted Supply

Certified Medical Supply

Indications & Clinical Uses

  • Lorbrena 100mg film-coated tablets contain lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that also penetrates the brain.
  • It is indicated for adults with metastatic non-small cell lung cancer whose tumours are ALK-positive as shown by an FDA-approved test.
  • In the European Union the identical lorlatinib product is sold by Pfizer as Lorviqua, approved for adults with ALK-positive advanced NSCLC either as first treatment or after alectinib, ceritinib or crizotinib-based therapy has stopped working.
  • The usual dose is 100 mg by mouth once daily, with or without food, continued until the disease progresses or side effects become unacceptable.
  • Tablets come in 25 mg and 100 mg strengths so the dose can be adjusted.
  • Lorbrena is prescribed and monitored by a cancer specialist.
  • Swallow tablets whole; do not chew, crush or split them.

Side Effects

  • Lorbrena (lorlatinib) causes side effects in at least one in five people, including swelling of the legs or face, numbness or tingling of the hands and feet, weight gain, tiredness, breathlessness, joint pain, diarrhoea, cough and raised blood cholesterol and triglycerides.
  • Distinctively, it affects the central nervous system: changes in mood such as irritability, anxiety or agitation, changes in thinking, memory, attention or speech, and less often psychotic symptoms or seizures.
  • The label carries no boxed warning, but it contraindicates strong CYP3A inducers because combining them with lorlatinib has caused severe, potentially fatal liver injury.
  • Tell your care team at once about confusion, hallucinations, personality change, slurred speech, seizures, a very slow pulse or fainting, or new breathlessness, cough and fever, which may mean lung inflammation.
  • Most CNS effects improve when the dose is reduced.

Precautions & Warnings

  • Lorbrena is contraindicated with strong CYP3A inducers because of the risk of serious, sometimes fatal liver toxicity; if you have been taking one, a washout period is required before starting.
  • Cholesterol and triglycerides must be checked before treatment, two weeks and one month after starting and regularly thereafter, and most patients need a lipid-lowering medicine.
  • Blood pressure, blood glucose, liver enzymes and heart rate also need monitoring, and lorlatinib can prolong the PR interval and cause AV block, so tell your team about conduction problems or a pacemaker.
  • Stop and report new cough, fever or breathlessness, because interstitial lung disease can occur.
  • Lorlatinib can harm an unborn baby: women should use effective non-hormonal contraception during treatment and for at least six months afterwards, and men with female partners for three months.
  • Do not drive if thinking or mood is affected.

Avoid Interactions

  • Strong CYP3A inducers, including rifampicin, carbamazepine, phenytoin, enzalutamide, mitotane and St John's wort, are CONTRAINDICATED with Lorbrena because they lower lorlatinib levels and have caused severe liver injury.
  • Moderate CYP3A inducers such as modafinil, bosentan and efavirenz should be avoided; if one is unavoidable the Lorbrena dose is raised to 125 mg.
  • Strong CYP3A inhibitors such as ketoconazole, itraconazole, clarithromycin and ritonavir, and grapefruit or grapefruit juice, raise lorlatinib levels and toxicity and should be avoided; if unavoidable the dose is reduced to 75 mg, and the same reduction applies with fluconazole.
  • Lorlatinib is itself a moderate CYP3A inducer, so it lowers levels of CYP3A substrates including some hormonal contraceptives, midazolam and certain statins and immunosuppressants.
  • Tell your healthcare provider about every medicine, herbal remedy and supplement.

References

Frequently Asked Questions

Lorbrena 100 mg (lorlatinib) treats ALK-positive metastatic non-small cell lung cancer in adults, confirmed by an approved test. It is an ALK tyrosine kinase inhibitor that also works against secondary deposits in the brain. In Europe the same lorlatinib product is sold as Lorviqua.

Simple Working Process

We have simplified the online drug ordering process into 4 easy steps to ensure
a safe, secure, and hassle-free experience for our customers.


Order Online

Place your order online and upload prescription in minutes with ease.



Order Confirmation

We verify your prescription and confirm your order quickly and securely.



Prescription Review

Reviewed by licensed pharmacists. Carefully processed and validated.

R

Receive Medicines

Approved order delivered fast, easy, and right to your doorstep or nearby Airport.



Global Standards. Trusted Care.

Trusted & Reliable – Your Partner in Global Distribution.

We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.